@article{oai:nagasaki-u.repo.nii.ac.jp:00014558,
 author = {Kanda, Shigeru and Miyata, Yasuyoshi and Kanetake, Hiroshi},
 journal = {Oncogene Proteins: Structure, Functions and Analyses},
 month = {},
 note = {Fes (also known as Fps), together with Fer, form the nonreceptor protein tyrosine kinase subfamily. The expression of Fes in normal tissues has been shown to be limited to monocytic hematopoietic cells, endothelial cells, and some neuronal and epithelial cells. Studies using mice expressing activated mutant Fes or cultured endothelial cells indicated that Fes might be involved in pathological angiogenesis, suggesting it could be a potential target for antiangiogenic therapy. Fes was initially identified as a protooncogene product. However, recent studies have indicated that Fes may act also as a tumor suppressor protein in some carcinomas, such as colon cancer, based on the identification of inactivating mutated Fes in colon cancer tissues and downregulated expression of Fes in some cancer cells. Thus, during treatment of these cancers, inhibition of Fes activity may stimulate progression of the pathological process. In this short communication, we will review the recent reports on the roles of Fes in tumor progression and discuss the problems that must be solved before targeting of this kinase in any anti-cancer therapy., Editors: Peter B. Murphy and Jason R. Clarke, Oncogene Proteins: Structure, Functions and Analyses, pp.209-221; 2008},
 pages = {209--221},
 title = {Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy},
 year = {2008}
}